Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

Thyroid Cancer in Isfahan Province, Iran; Prevalence and Demographic Characteristics

Zahra Tolou Ghamari 1 , *
Author Information
1 Isfahan Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: 8 (1); e86864
  • Published Online: January 13, 2019
  • Article Type: Research Article
  • Received: November 28, 2018
  • Revised: December 26, 2018
  • Accepted: December 29, 2018
  • DOI: 10.5812/jjcdc.86864

To Cite: Tolou Ghamari Z. Thyroid Cancer in Isfahan Province, Iran; Prevalence and Demographic Characteristics, Jundishapur J Chronic Dis Care. Online ahead of Print ; 8(1):e86864. doi: 10.5812/jjcdc.86864.

Abstract
Copyright © 2019, Jundishapur Journal of Chronic Disease Care. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Shah JP. Thyroid carcinoma: Epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015;13(4 Suppl 4):3-6. [PubMed: 26430868]. [PubMed Central: PMC5526593].
  • 2. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161(5):1549-56. doi: 10.1016/S0002-9440(10)64433-1. [PubMed: 12414503]. [PubMed Central: PMC1850764].
  • 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442. [PubMed: 29313949].
  • 4. Safavi A, Azizi F, Jafari R, Chaibakhsh S, Safavi AA. Thyroid cancer epidemiology in Iran: A time trend study. Asian Pac J Cancer Prev. 2016;17(1):407-12. [PubMed: 26838247].
  • 5. Heidari Z, Abdani M, Mansournia MA. Insulin resistance associated with differentiated thyroid carcinoma: Penalized conditional logistic regression analysis of a matched case-control study data. Int J Endocrinol Metab. 2018;16(1). e14545. doi: 10.5812/ijem.14545. [PubMed: 29696038]. [PubMed Central: PMC5903382].
  • 6. Davies L, Morris LG, Haymart M, Chen AY, Goldenberg D, Morris J. American association of clinical endocrinologists and american college of endocrinology disease state clinical review: The increasing incidence of thyroid cancer. Endocr Pract. 2015;21(6):686-96. doi: 10.4158/EP14466.DSCR. [PubMed: 26135963]. [PubMed Central: PMC4923940].
  • 7. Radwan H, Hasan H, Ballout RA, Rizk R. The epidemiology of cancer in the United Arab Emirates: A systematic review. Medicine (Baltimore). 2018;97(50). e13618. doi: 10.1097/MD.0000000000013618. [PubMed: 30558043].
  • 8. Khader YS, Sharkas GF, Arkoub KH, Alfaqih MA, Nimri OF, Khader AM. The epidemiology and trend of cancer in Jordan, 2000-2013. J Cancer Epidemiol. 2018;2018:2937067. doi: 10.1155/2018/2937067. [PubMed: 30416523]. [PubMed Central: PMC6207872].
  • 9. Soheylizad M, Khazaei S, Jenabi E, Delpisheh A, Veisani Y. The relationship between human development index and its components with thyroid cancer incidence and mortality: Using the decomposition approach. Int J Endocrinol Metab. 2018;16(4). e65078. doi: 10.5812/ijem.65078. [PubMed: 30464773]. [PubMed Central: PMC6218660].
  • 10. Modirian M, Cheraghi Z, Rahimzadeh S, Moghaddam SS, Jarrahi AM. Burden assessment of thyroid cancer in Iran from 1990 to 2010: Lessons obtained from global burden of disease report 2010. Asian Pac J Cancer Prev. 2015;16(17):7743-8. [PubMed: 26625791].
  • 11. Mazdak H, Tolou-Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. Arab J Urol. 2018;16(2):206-10. doi: 10.1016/j.aju.2017.11.017. [PubMed: 29892483]. [PubMed Central: PMC5992262].
  • 12. Ghamari ZT. Prevalence of stomach cancer in Isfahan province, Iran. Gulf J Oncolog. 2018;1(28):42-5. [PubMed: 30344133].
  • 13. Tolou Ghamari Z. Prevalence of lung cancer in Isfahan province, Iran. J Egypt Natl Canc Inst. 2018;30(2):57-9. doi: 10.1016/j.jnci.2018.03.001. [PubMed: 29691096].
  • 14. Tolou-Ghamari Z. Prevalence of skin cancer in Isfahan province, Iran. Jentashapir J Health Res. 2018;9(2). doi: 10.5812/jjhr.82743.
  • 15. Tolou-Ghamari Z. Prevalence of breast cancer in isfahan province, Iran. Women Health Bull. 2018;5(4). e82678. doi: 10.5812/whb.82678.
  • 16. Ghamari ZT, Tadayon F, Mazdak H. Prevalence of liver cancer in Isfahan province, Iran. Indonesian J Cancer. 2018;12(2):56-9.
  • 17. Sokouti M, Montazeri V, Fakhrjou A, Samankan S, Goldust M. Thyroid cancer, clinical and hystopathological study on patients under 25 years in Tabriz, Iran (2000-2012). Pak J Biol Sci. 2013;16(24):2003-8. [PubMed: 24517019].
  • 18. Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, et al. Endocrine cancer in Iran: Based on cancer registry system. Indian J Cancer. 2006;43(2):80-5. [PubMed: 16790945].
  • 19. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-9. doi: 10.2217/fon.10.127. [PubMed: 21142662]. [PubMed Central: PMC3077966].
  • 20. Ahmadi A, Salehi F. Evaluation of observed and the expected incidence of common cancers: An experience from Southwestern of Iran, 2010-2014. J Res Med Sci. 2018;23:4. doi: 10.4103/jrms.JRMS_788_17. [PubMed: 29456561]. [PubMed Central: PMC5813294].
  • 21. Jafary F, Aminorroaya A, Amini M, Adibi A, Sirous M, Roohi E, et al. Thyroid incidentaloma in Isfahan, Iran - a population-based study. Endokrynol Pol. 2008;59(4):316-20. [PubMed: 18777502].
  • 22. Deandrea M, Gallone G, Veglio M, Balsamo A, Grassi A, Sapelli S, et al. Thyroid cancer histotype changes as observed in a major general hospital in a 21-year period. J Endocrinol Invest. 1997;20(2):52-8. [PubMed: 9125483].
  • 23. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: The influence of access to care. Thyroid. 2013;23(7):885-91. doi: 10.1089/thy.2013.0045. [PubMed: 23517343]. [PubMed Central: PMC3704124].
  • 24. Tolou-Ghamari Z, Habibabadi JM, Palizban AA. Evidence-based pharmacotherapy of epilepsy. Arch Neurosci. 2015;2(1):6. doi: 10.5812/archneurosci.18468.
  • 25. Tolou-Ghamari Z, Mortazavi M, Palizban AA, Najafi MR. The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation. Adv Biomed Res. 2015;4:59. doi: 10.4103/2277-9175.151876. [PubMed: 25802828]. [PubMed Central: PMC4361960].
  • 26. Tolou-Ghamari Z, Palizban AA. Laboratory monitoring of cyclosporine pre-dose concentration (C0) after kidney transplantation in Isfahan. Iran J Med Sci. 2003;28(2):81-5.
  • 27. Bushnik T, Evans WK. Sociodemographic characteristics associated with thyroid cancer risk in Canada. Health Rep. 2018;29(10):3-11. [PubMed: 30329144].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments